P/E ratio for Marksans Pharma (MARKSANS.NS)
P/E ratio as of May 2024 (TTM): 24.1
According to Marksans Pharma 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 24.1231. At the end of 2022 the company had a P/E ratio of 11.1.
P/E ratio history for Marksans Pharma from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 11.1 | 7.73% |
| 2021 | 10.3 | -16.13% |
| 2020 | 12.3 | 52.79% |
| 2019 | 8.07 | -56.84% |
| 2018 | 18.7 | -61.63% |
| 2017 | 48.7 | -71.88% |
| 2016 | 173 | 320.33% |
| 2015 | 41.2 | 65.69% |
| 2014 | 24.9 | 274.59% |
| 2013 | 6.64 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.